Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported Cash from Financing Activities of -$776000.0 for Q1 2026, up 41.39% on a YoY basis from -$548837.6 in Q1 2025, and down 21.25% sequentially from -$640000.0 in Q4 2025.
Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 15 years of Cash from Financing Activities data on file, last reported at -$776000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 41.39% year-over-year to -$776000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.4 million (down 59.43% YoY), and the FY2025 full-year result was -$2.9 million, down 1774.84% from the prior year.
- Cash from Financing Activities eased to -$776000.0 in Q1 2026, from -$640000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $605000.0 in Q4 2022 to a low of -$1.3 million in Q1 2025.
- A 4-year average of -$344777.8 and a median of -$425000.0 in 2025 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities plunged 312.9% in 2025 and surged 41.39% in 2026, its largest moves.
- Tracing VNDA's Cash from Financing Activities over 4 years: stood at $605000.0 in 2022, then plunged by 125.62% to -$155000.0 in 2024, then sank by 312.9% to -$640000.0 in 2025, then declined by 21.25% to -$776000.0 in 2026.
- Business Quant data shows VNDA's Cash from Financing Activities at -$776000.0 in Q1 2026, -$640000.0 in Q4 2025, and -$517000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | -776,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -776,000.00 |
| Mar 31, 2026 | -776,000.00 |
| Dec 31, 2025 | -640,000.00 |
| Dec 31, 2025 | -640,000.00 |
| Sep 30, 2025 | -517,000.00 |
| Sep 30, 2025 | -517,000.00 |
| Jun 30, 2025 | -425,000.00 |
| Jun 30, 2025 | -425,000.00 |
| Mar 31, 2025 | -1.32 Mn |
| Mar 31, 2025 | -1.32 Mn |
| Dec 31, 2024 | -155,000.00 |
| Dec 31, 2024 | -155,000.00 |
| Dec 31, 2022 | 605,000.00 |
| Dec 31, 2022 | 605,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Jun 30, 2022 | 125,000.00 |
| Jun 30, 2022 | 125,000.00 |
| Dec 31, 2021 | 1.04 Mn |
| Dec 31, 2021 | 1.04 Mn |